FDA Approves Biogen’s Plegridy Intramuscular Administration for Multiple SclerosisAutoimmune Disorders, Biogen, Blockbusters, FDA, Intramuscular Injection, Relapsing-Remitting Multiple SclerosisThe U.S. Food and Drug Administration approved Biogen Inc.’s new intramuscular injection route of administration for Plegridy (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis. Read more February 1, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-02-01 07:30:282021-02-01 11:36:19FDA Approves Biogen’s Plegridy Intramuscular Administration for Multiple Sclerosis
